The National Institutes of Health has awarded the University of Alabama at Birmingham Center for Clinical and Translational Science $33.59 million over four years to continue the center’s programs advancing translational research.
An Arizona drug company will patent the small peptide drug.
The challenge is to stifle the binding of inhibitory antibodies but retain activity of a blood enzyme.
Rates of vision impairment are high among seniors living in subsidized housing, suggesting an increased need for widespread vision screening.
Many patients diagnosed with type 1 diabetes as adults do not fit the standard profile for a diabetes diagnosis; they are younger, are relatively fit and have little if any belly fat.
The mimicry of bone cells by multiple myeloma is driven by overexpression of Runx2, the master regulator of bone formation.
Virginia Wadley, Ph.D., says until this new JAMA study, whether or not stroke survivors are at-risk over the long term was an unknown.
New research identifies an epigenetic cause for why patients with temporal lobe epilepsy tend to have memory loss, and suggests a potential way to reverse that loss.
Four of the most world renowned scholars and influential leaders in the field of infectious disease research will come to UAB to honor the legacy of the late Distinguished Professor Charles Alford, M.D.
UAB researchers find a chemical pathway — a glutamate transporter — that may be causing seizures and shorten survival rates for patients with brain tumors.